How to Cite
Abstract
Metabolic syndrome is considered a cluster of risk factors that include abdominal obesity, insulin resistance, elevated blood pressure, and atherogenic dyslipidemia. The origin of metabolic syndrome is due to a combination of genetic and epigenetic factors, lifestyle and environmental factors. Cardiovascular disease and type 2 diabetes mellitus are the main coexisting conditions. Diagnosis is made when three or more of the five criteria are present, including: 1) systolic blood pressure ≥130 mm/Hg and/or diastolic blood pressure ≥85 mm/Hg, 2) triglyceride levels ≥150 mg/dL, 3) HDL levels <40 mg/dL in men and <50 mg/dl in woman, 4) glucose levels ≥100 mg/dL and 5) abdominal circumference ≥ 88 cm for women and ≥ 102 cm in men. Treatment is based on both pharmacological and non-pharmacological measures. Metabolic syndrome is a condition that should always be kept in mind and should be excluded in the risk population. Anthropometric measurements are a good method of early detection to be able to start with complementary laboratory tests and thus diagnose the pathology in a timely manner and thus avoid long-term repercussions.
Keywords
References
Reisinger C, Nkeh-Chungag BN, Fredriksen PM, Goswami N. The prevalence of pediatric metabolic syndrome-a critical look on the discrepancies between definitions and its clinical importance. Int J Obes (Lond). 2021 Jan;45(1):12-24. DOI: https://doi.org/10.1038/s41366-020-00713-1
Chan SMH, Selemidis S, Bozinovski S, Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther. 2019 Jun;198:160-188. DOI: https://doi.org/10.1016/j.pharmthera.2019.02.013
DeBoer MD. Assessing and Managing the Metabolic Syndrome in Children and Adolescents. Nutrients. 2019 Aug 2;11(8):1788. DOI: https://doi.org/10.3390/nu11081788
Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022 Jan 12;23(2):786. DOI: https://doi.org/10.3390/ijms23020786
Velazquez J, Herrera H, Encalada-Torres L, Wong S. Valor diagnóstico de variables lipídicas y antropométricas en las disfunciones metabólicas. Acta Bioquímica. 2018; 52(3): 293-301, 2018
Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018 Feb 26;20(2):12. DOI: https://doi.org/10.1007/s11906-018-0812-z
Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front Cardiovasc Med. 2020 Feb 25;7:22. DOI: https://doi.org/10.3389/fcvm.2020.00022
Zhang W, Zhao Z, Sun X, Tian X. Prevalence of Metabolic Syndrome According to Absolute and Relative Values of Muscle Strength in Middle-Aged and Elderly Women. Int J Environ Res Public Health. 2021 Aug 27;18(17):9073. DOI: https://doi.org/10.3390/ijerph18179073
Fauci A, Harrison, T. Harrison. Manual de Medicina Interna. 19th ed. México, D.F.: McGraw-Hill, 2010; pp.2449-2454.
Hernández Rodríguez J, Duchi Jimbo PN. Índice cintura/talla y su utilidad para detectar riesgo cardiovascular y metabólico. Rev cuba endocrinol [Internet]. 2018;26(1):66–76. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S156129532015000100006
Brahim Q, Ahsan M. Measurement of Visceral Fat, Abdominal Circumference and Waist-hip Ratio to Predict Health Risk in Males and Females. Pak J Biol Sci. 2019 Jan;22(4):168-173. DOI: https://doi.org/10.3923/pjbs.2019.168.173
McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018 Jan-Feb;36(1):14-20. DOI: https://doi.org/10.1016/j.clindermatol.2017.09.004
Shi Y, Zou Y, Shen Z, Xiong Y, Zhang W, Liu C, Chen S. Trace Elements, PPARs, and Metabolic Syndrome. International Journal of Molecular Sciences. 2020; 21(7):2612. DOI: https://doi.org/10.3390/ijms21072612
Myers J, Kokkinos P, Nyelin E. Physical Activity, Cardiorespiratory Fitness, and the Metabolic Syndrome. Nutrients. 2019 Jul 19;11(7):1652. DOI: https://doi.org/10.3390/nu11071652
Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Delgado V et al. Guía ESC/EAS 2019 sobre el tratamiento de las dislipidemias: modificación de los lípidos para reducir el riesgo cardiovascular. Rev. Esp. Cardiol. 2020; 73(5): 403.e1-403.e70. DOI : https://doi.org/10.1016/j.recesp.2019.10.031
Gorostide M, Gijón-Conde T, de la Sierra A, Rodilla E, Rubio E, Vinyoles E. Guía práctica sobre el diagnóstico y tratamiento de la hipertensión arterial en España, 2022. Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hieprtensión Arterial (SEH-LELHA). Hipertensión y riesgo cardiovascular. 2022; 39(1): 174-194. DOI: https://doi.org/10.1016/j.hipert.2022.09.002
Santos E. Resistencia a la insulina: Revisión de literatura. Revista médica Hondureña. 2022; 90(1): 1-94. DOI: https://doi.org/10.5377/rmh.v90i1.13824
Araujo CM, Castillo KM, Londoño JC, Revelo KM. Relación del síndrome metabólico en el riesgo de enfermedades cardiovasculares. Revista Científica Mundo de la Investigación y el Conocimiento. 2021; 5(1)120-128. DOI: https://doi.org/10.26820/recimundo/5.(1).enero.2021.120-128
González A, Chávez JA, Elizondo S, González A, León JI, Ochoa C. Metabolic Syndrome and Cardiovascular disease: A Health Challenge in Mexico. Archives of Medical Research. 2018; 49(8): 516-521. DOI: https://doi.org/10.1016/j.arcmed.2018.10.003
Hudish LI, Reusch J, Sussel L. β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. J Clin Ivest. 2019; 129(10): 4001-4008. DOI: https://doi.org/10.1172/JCI129188
Salamonowicz MM, Zalewska A, Maciejczyk M. Oral consequences of obesity and metabolic syndrome in children and adolescents. Dent Med Probl. 2019 Jan-Mar;56(1):97-104. DOI: https://doi.org/10.17219/dmp/102620
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2023 Array